newsfilter
← Latest News
GlobeNewswire·

Prenetics’ IM8 Reports Q3 2026 Revenue Growth of 266% YoY; Earliest Customers Have Returned More Than 3x Their Acquisition Cost in Under Two Years; Reaffirms FY 2026 Total Revenue Guidance of $220–230 Million and FY 2027 IM8 Revenue Guidance of $400 Million+

  • Prenetics reported Q3 2026 total revenue of $64.1 million, a 228% year-over-year increase that exceeded its guidance range of $63–64 million.
  • IM8 brand revenue reached $62.9 million, up 266% year-over-year, surpassing the $61.5–62.5 million guidance range for the seventh consecutive record quarter.
  • September 2026 was IM8's strongest month with $23.7 million in revenue, establishing an annualized revenue run-rate of approximately $284 million.
  • The company recorded a net loss of $25.4 million, including a $7.2 million non-cash fair-value loss on warrant liabilities, while Adjusted EBITDA loss narrowed to $12.7 million (20% of revenue) from 39% in Q2.
  • Contribution Profit was $30.6 million, representing a 48% contribution margin.
  • Adjusted Free Cash Flow was positive at $4.1 million, driven by $31.6 million in net fundings under the General Catalyst Customer Value Fund facility offsetting $27.5 million in net cash used in operating activities.
  • Cash and current financial assets grew to $111.5 million as of September 30, 2026, from $109.4 million at June 30, 2026.
  • Cohort analysis shows the 27,000 customers acquired in Q1 2025 have returned 4.1x their acquisition cost in gross profit in under two years, with the next 91,000 customers projected to reach the 3-to-1 benchmark in early 2027.
  • Customer Acquisition Cost declined to approximately $285 for the second consecutive quarter despite record acquisition spending.
  • Prenetics reaffirmed FY2026 total revenue guidance of $220–230 million and FY2027 IM8 revenue guidance of $400 million or more.
  • The company raised its second-half 2026 Adjusted EBITDA loss expectation to $30–35 million from the previous $8–12 million guidance to fund increased customer acquisition investments.
  • Planned product launches not included in current guidance include IM8 Hydration in Q1 2027, Care Bears by IM8 in H1 2027, and retail expansion plus entry into China by end of 2027.
  • Prenetics divested non-core assets including ACT Genomics, Europa, and Insighta, with results classified as discontinued operations under IFRS 5.
Company
Prenetics Global Limited
Keywords
Nasdaq:PRE, Prenetics Global Limited